Preimplantation genetic testing has fundamentally changed IVF practice for many patient populations, with the Fertility Services Market reflecting the rapid adoption of PGT-A for chromosomal aneuploidy screening and PGT-M for monogenic disease testing that are improving implantation rates, reducing miscarriage, and enabling prevention of heritable genetic diseases for families with known genetic conditions.

PGT-A screens IVF embryos for numerical chromosomal abnormalities — aneuploidies — before transfer selection, identifying the chromosomally normal euploid embryos whose implantation rates substantially exceed those of unscreened embryos in older women where aneuploidy rates increase dramatically with maternal age. For women over thirty-eight, where greater than fifty percent of embryos may be aneuploid, PGT-A selection of euploid embryos dramatically improves per-transfer success rates and reduces the miscarriage risk associated with chromosomally abnormal embryo transfer.

Next-generation sequencing has replaced array comparative genomic hybridization as the PGT-A technology platform, providing higher resolution chromosomal analysis, simultaneous detection of segmental chromosomal imbalances alongside whole chromosome aneuploidies, and improved detection of mosaic embryos containing mixtures of euploid and aneuploid cells. The clinical significance of mosaic embryo transfer — whether mosaics should be transferred when no euploid embryos are available — remains an active area of research generating ongoing guidance evolution.

PGT-M enables couples carrying mutations for serious monogenic disorders — including BRCA1/2, cystic fibrosis, spinal muscular atrophy, and Huntington disease — to select embryos unaffected by the familial mutation before transfer, preventing transmission of severe genetic diseases that previously required prenatal diagnosis or accepting reproductive risk.

Do you think PGT-A will become standard practice for all IVF cycles regardless of maternal age as sequencing costs continue decreasing?

FAQ

What is PGT-A in IVF? Preimplantation genetic testing for aneuploidy screens IVF embryos for chromosomal abnormalities before transfer, selecting chromosomally normal embryos that implant at higher rates and miscarry less frequently than unscreened embryos.

Who benefits most from PGT-A? Women over thirty-five, those with recurrent miscarriage, recurrent IVF failure, and couples with chromosomal translocations benefit most from PGT-A, where aneuploidy rates are highest and embryo selection most clinically impactful.

What diseases can PGT-M prevent? PGT-M can test for any monogenic disorder with a known causative mutation, enabling selection of unaffected embryos for diseases including cystic fibrosis, BRCA mutations, Huntington disease, spinal muscular atrophy, and many other heritable conditions.

#FertilityServices #PGTtesting #PreimplantationGenetics #IVFgenetics #EmbryoSelection #GeneticTesting